SCHEDULE 13G/A: Decheng Capital Entities Disclose 8.4% Passive Stake in CG Oncology

Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and affiliated entities, including Xiangmin Cui, have filed an amended Schedule 13G disclosing a combined passive beneficial ownership of 8.4% in CG Oncology, Inc. as of December 31, 2024.

Summary

• Decheng Capital Global Life Sciences Fund IV, L.P. (Fund IV) beneficially owns 5,315,954 shares, representing 7.0% of CG Oncology's common stock.
• Decheng Capital Management IV (Cayman), LLC (GP IV), as the general partner of Fund IV, also beneficially owns 5,315,954 shares, representing 7.0%.
• Decheng Capital Global Healthcare Fund (Master), LP (Healthcare) beneficially owns 1,055,715 shares, representing 1.4% of CG Oncology's common stock.
• Decheng Capital Global Healthcare GP, LLC (Healthcare GP), as the general partner of Healthcare, also beneficially owns 1,055,715 shares, representing 1.4%.
• Xiangmin Cui, as the manager of GP IV and indirect managing member of Healthcare GP, beneficially owns a total of 6,371,669 shares, representing 8.4% of CG Oncology's common stock.
• All beneficial ownership percentages are calculated based on 76,037,858 shares of CG Oncology's common stock outstanding as of December 16, 2024.
• The reporting persons expressly disclaim status as a "group" for the purposes of this Schedule 13G filing.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing passive beneficial ownership, providing factual information without expressing positive or negative sentiment regarding the company's performance or outlook.

Positives

• The disclosure indicates continued significant investment by Decheng Capital entities in CG Oncology.
• The filing is a routine compliance update, reflecting transparency in ownership.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of passive beneficial ownership by investment funds in a publicly traded biotechnology company, CG Oncology, which operates in the oncology sector. Such filings provide transparency regarding significant institutional holdings, which can be a factor in market perception and corporate governance, particularly in the biotech industry where capital investment is crucial.

Related Party Transactions

• The filing details the beneficial ownership structure where Xiangmin Cui, as the manager of Decheng Capital Management IV (Cayman), LLC and indirect managing member of Decheng Capital Global Healthcare GP, LLC, shares voting and investment authority over the shares held by Decheng Capital Global Life Sciences Fund IV, L.P. and Decheng Capital Global Healthcare Fund (Master), LP. This establishes a control relationship among the reporting entities and Dr. Cui regarding the shares of CG Oncology.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Company Management: Awareness of significant passive investors and their collective stake.

Key Dates

Keywords

CG Oncology, Decheng Capital, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Oncology, Investment Fund, Xiangmin Cui, SEC Filing